Major human drug trial underway for Alzheimer's

May 23, 2013, CORDIS
Major human drug trial underway for Alzheimer's
Credit: Shutterstock

A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest in EU-funded studies, which are being made public to highlight the European Month of the Brain.

This major 18-month study is NILVAD ('Nilvadipine in Alzheimer's Disease'), which has funding of EUR 6 million from the 7th Framework Programme for Research and Technological Development. Leading this five-year project to an international level is Professor Brian Lawlor, from Trinity College Dublin. His research interests are in the early detection, diagnosis and treatment of AD, as well as the and treatment of behavioural and in dementia and .

Alzheimer's is the most common form of dementia, which causes problems with memory, thinking and behaviour. Although there are around 100 different types of dementia, AD is the most common form, affecting 62 % of those living with dementia. The disease affects more than 15 million individuals worldwide and around 5 million . As a result it remains one of the most costly diseases in society, which amounts to more than EUR 440 000 million each year.

The rise in numbers is attributed to advances in public health and medical care that enables people to live much longer than they used to. While one in 25 people aged 70 to 79 has a form of , this rises to one in six people over the age of 80.

However, Professor Lawlor is hopeful that collaborating with Alzheimer's experts from ten countries will prove successful, given the fact that for the disease have not come to fruition since 2002. This, despite many promising lines of research which have come to nothing.

However, the NILVAD project, has so far, shown more than just promise. The drug, nilvadipine, is already approved for human use in , and a pilot trial has demonstrated that the drug could be safe in the treatment of AD.

Professor Lawlor says, 'We are trying to see if it alters the rate of progression of the disease. Animal trials gave promising results and the earlier pilot trial did give an efficacy signal as well.'

The trial will consist of male and female patients with mild to moderate AD aged between 50 and 90. It is hoped, that if this trial is successful, nilvadipine could represent an advance in the treatment of AD patients. Most importantly it would have a major impact on the health and social care costs incurred in Europe by this neurodegenerative disorder.

Explore further: Nonmelanoma skin cancer tied to lower Alzheimer's risk

More information: NILVAD www.nilvad.eu/

Related Stories

Nonmelanoma skin cancer tied to lower Alzheimer's risk

May 16, 2013
(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.

Could a common blood pressure drug slow down the progression of Alzheimer's?

March 4, 2013
A ground-breaking trial that hopes to discover if a drug commonly used to treat high blood pressure could slow down the progression of Alzheimer's disease (AD) will begin shortly.

Drugs targeting blood vessels may be candidates for treating Alzheimer's

March 7, 2013
(Medical Xpress)—University of British Columbia researchers have successfully normalized the production of blood vessels in the brain of mice with Alzheimer's disease (AD) by immunizing them with amyloid beta, a protein ...

Drug shows promise in animal model of Alzheimer's and Parkinson's with dementia

October 26, 2012
New research presented in October at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline ...

Scientists identify Buphenyl as a possible drug for Alzheimer's disease

March 11, 2013
(Medical Xpress)—Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer's disease. Hyperammonemia is a life-threatening condition that can affect patients at ...

Study finds late-life depression associated with increased risk for dementia

May 2, 2013
(Medical Xpress)—Late-life depression is associated with an increased risk for all-cause dementia, Alzheimer's disease and, most predominantly, vascular dementia, according to the results of a new meta-analysis published ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.